forex signal system trading: Harvard-trained doctor launches new startup targeting Big Pharma

You are receiving this as a part of your subscription to The Startup Investor. To remove your email from this list, unsubscribe here.

Dear The Startup Investor Reader,

This $40 million startup just put Big Pharma on notice.

They're emerging from stealth mode with 27 treatments for rare and deadly diseases, which, in just a few years, could be worth $1 billion each.

Their CEO built and sold two multibillion-dollar pharmaceutical companies over his 30-year career before co-founding this one.

The man in charge of bringing their treatments to market helped launch the best-selling drug of all time. Which makes $19 billion a year in sales.

They've got a "secret weapon" for navigating the FDA... the man who helped design the process is one of their founding members.

He's helped over 100 drugs get approved and overseen the approval of countless more.

And their leader is a famous, Harvard-trained doctor who treated over 25,000 patients for previously "uncurable" conditions.

He was willing to do what few other doctors would to develop these treatments.

And now that he has them, this doctor - and his team of pharmaceutical-industry titans - are coming for the big boys.

In this interview, he reveals his plans to grow his startup to a $21.6 billion behemoth in just a few years.

It's only up for a limited time, so watch now.

Best,

Bob Keppel
Co-Founder, National Institute for Cannabis Investors

P.S. This company is still private, but they just released a limited number of $1 shares. Get all the details here.

Please do not reply to this email. It was sent from an unmonitored mailbox.

You are receiving this e-mail at phanphuongthanh89.822152@blogger.com, as part of your subscription to The Startup Investor. To remove your email from this list: unsubscribe here.

To cancel, or for any other questions or requests, please contact our Customer Service team:
Online
Phone: 866-310-1498 (North America) 443-221-6766 (International)
Mail: The Startup Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201
Our Customer Service team is available Monday ‑ Friday between 9:00 AM and 5:00 PM ET.

© 2020 Angels & Entrepreneurs. All Rights Reserved.
Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice.

We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Angels & Entrepreneurs. 1125 N Charles Street, Baltimore, MD 21201.

Website | Privacy Policy | Terms & Conditions

Harvard-trained doctor launches new startup targeting Big Pharma

No comments:

Post a Comment